Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28834340 | 1.00 | USP30 (0.50) | USP30GPR119CNR1BTKPARP1 | |
| SCHEMBL29862554 | 1.00 | USP30 (0.50) | USP30GPR119CNR1BTKPARP1 | |
| SCHEMBL28834031 | 1.00 | USP30 (0.50) | USP30GPR119CNR1BTKPARP1 | |
| SCHEMBL28834030 | 1.00 | USP30 (0.50) | USP30GPR119CNR1BTKPARP1 | |
| SCHEMBL23359875 | 0.94 | GPR119 (0.51) | USP30GPR119CNR1EPHX2 | |
| SCHEMBL28834064 | 0.92 | USP30 (0.49) | USP30GPR119CNR1BTKPARP1 | |
| SCHEMBL29933464 | 0.92 | USP30 (0.49) | USP30GPR119CNR1BTKPARP1 | |
| SCHEMBL28834065 | 0.92 | USP30 (0.49) | USP30GPR119CNR1BTKPARP1 | |
| SCHEMBL28834126 | 0.90 | USP30 (0.49) | USP30CNR1BTKPIM1PIM2 | |
| SCHEMBL29862707 | 0.89 | USP30 (0.51) | USP30GPR119CNR1BTKPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | USP30 1231/4885GPR119 1940/4885CNR1 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.